Novo Nordisk's Sickle Cell Disease Drug Etavopivat Meets Co-primary Endpoints in Late-stage Trial
Idag, 12:27
06:27 AM EDT, 04/20/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) said Monday its sickle cell disease drug etavopivat achieved both co-primary endpoints during a phase 3 trial.
The randomized, double-blinded Hibiscus study showed a 27% reduction in vaso-occlusive crises and superior improvement in hemoglobin response with 400 milligrams of etavopivat, compared with placebo. The trial involved 385 patients aged 12 years or older.
The Danish drugmaker plans to apply for the first regulatory approval of etavopivat in the second half.
Ämnen i artikeln
Novo Nordisk's Sickle Cell Disease Drug Etavopivat Meets Co-primary Endpoints in Late-stage Trial
Idag, 12:27
06:27 AM EDT, 04/20/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) said Monday its sickle cell disease drug etavopivat achieved both co-primary endpoints during a phase 3 trial.
The randomized, double-blinded Hibiscus study showed a 27% reduction in vaso-occlusive crises and superior improvement in hemoglobin response with 400 milligrams of etavopivat, compared with placebo. The trial involved 385 patients aged 12 years or older.
The Danish drugmaker plans to apply for the first regulatory approval of etavopivat in the second half.
Ämnen i artikeln
Banker
Analys
-160x160.jpg&w=3840&q=75)
